Novo Nordisk Enters $600M Partnership for Next-Gen Obesity Therapies; Shiseido Reports Q1 Revenue of RMB 12B with RMB 2.68B from China

May 12, 2024 17:30 CST Updated 17:30

Metaphore Biotechnologies

AI Drug Discovery Platform

丨Novo Nordisk Reaches $600 Million Collaboration to Develop Next-Generation Weight Loss Drugs

May 9,Novo NordiskBiological entities incubated by FlagshipTechnology CompanyMetaphore BiotechnologiesAchieveTo cooperate and jointly develop up to two next-generation obesity treatment drugs.

▲ImageSourceFromPharmaCube

Under the terms of the agreement, Novo Nordisk may pay up to $600 million in upfront, development, and commercial milestone payments, as well as tiered royalties on annual net sales of licensed products, to be shared by Metaphore Biotechnologies and Pioneering Medicine. Novo Nordisk will also reimburse R&D costs and participate in future financing rounds of Metaphore. This collaboration will leverage Metaphore's MIMIC platform to design solutions targetingGLP-1Receptor and related biological multi-target therapies aim to develop long-acting drugs that do not require frequent administration. Metaphore Biotechnologies will collaborate with Pioneering Medicines and Novo Nordisk to advance the project through foundational research and preclinical development. Afterwards, Novo Nordisk can move the project into clinical research. Metaphore Biotechnologies...Omega TherapeuticsAndCellarityThe third biotechnology company incubated by Flagship Pioneering and partnered with Novo Nordisk. This also represents a further deepening of the strategic R&D collaboration between Novo Nordisk and Flagship on cardiovascular-metabolic and rare disease drugs.

丨Shiseido Q1 Revenue 12 Billion Yuan, China Market Contributed 2.68 Billion Yuan

5Month10On [date], Shiseido Group released its financial report as of3Month31Day's2024Financial Data for the First Quarter of the Fiscal Year.During the reporting period, Shiseido Group's net sales2495100 million yen (approximatelyRMB120Billion yuan, at the reported exchange rateJPY20.7/CNYCalculation, the same below), year-on-year growth3.9%; Operating profit decreased87.45100 million yen (approximatelyRMB4100 million yuan); Profit attributable to owners of the parent company decreased33100 million yen (approximatelyRMB1.59100 million yuan); core operating profit is113100 million yen (approximatelyRMB5.5(billion yuan), a year-on-year decrease12Billion yen, but exceeded expectations, compared to the previous quarter (2023YearQ4) Core Operating Profit30Million yen, profitabilitySteady improvement.

Revenue in the Chinese market was approximately 55.5 billion yen (about 2.68 billion yuan), accounting for 22.2%. Clé de Peau Beauté and NARS achieved steady growth, but under the impact of the nuclear wastewater incident, the Shiseido brand experienced negative quarterly growth once again.

▲Image source: Shiseido financial report

丨A Medical Aesthetic Institution in Guicheng Had Its License Revoked and Fined 50,000 Yuan!

RecentlyRecently, a citizen reported that her friend fell into a coma after undergoing autologous fat breast augmentation at a medical beauty clinic in Guicheng.Law enforcement officers at the district and street levels conducted multiple on-site inspections of the clinic and questioned relevant personnel to obtain evidence, confirming the situation of the clinic.There exists practice of breast augmentation beyond the registered scope, forgery of medical records by the legal representative of the institution, and failure of nursing staff to implement the surgical safety checklist system as required.Illegal acts.

In accordance with relevant regulations, the Health Bureau of Nanhai District imposed combined penalties for various illegal activities of this outpatient department.Confiscation of Illegal Proceeds22800Yuan, Fine50000Yuan, andRevocation of the "Medical Institution Practice License"Administrative penalty.